Coherus Oncology, Inc.
Clinical trials sponsored by Coherus Oncology, Inc., explained in plain language.
Biopharmaceutical company focused on oncology immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug CHS-114 enters first human tests Results expected Sep 2026 (estimated)
- New cocktail aims to shrink untreatable liver tumors Results expected Sep 2027 (estimated)
-
Immunotherapy-Chemo cocktail shows promise for Tough-to-Treat throat cancer
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people with recurrent or metastatic nasopharyngeal cancer that hasn't been treated before. About 100 participants will receive the combination int…
Phase 4 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New cancer cocktail enters human testing
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…
Phase 1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC